Uni Eropa - Islandia - EMA (European Medicines Agency)

novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - augnlækningar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 125 míkróg/5 míkróg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 50 míkróg/5 míkróg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - fluticasonum própíónat - nefúði, dreifa - 50 míkróg/skammt

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

h. lundbeck a/s* - zuclopenthixolum díhýdróklóríð - filmuhúðuð tafla - 10 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

h. lundbeck a/s* - zuclopenthixolum díhýdróklóríð - filmuhúðuð tafla - 2 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

h. lundbeck a/s* - zuclopenthixolum decanóat - stungulyf, lausn - 200 mg/ml

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

h. lundbeck a/s* - zuclopenthixolum acetas - stungulyf, lausn - 50 mg/ml